Results 221 to 230 of about 468,836 (265)
Some of the next articles are maybe not open access.
Clinical Pharmacology of Lacidipine
Journal of Cardiovascular Pharmacology, 1991The safety and tolerability of lacidipine was assessed in a volunteer population, and its pharmacodynamic and pharmacokinetic profiles evaluated. In normotensive subjects, single oral doses of 3-5 mg of lacidipine produced a dose-related fall in peripheral vascular resistance.
S T, Hall +4 more
openaire +2 more sources
Clinical pharmacology of thalidomide
European Journal of Clinical Pharmacology, 2001Thalidomide has a chiral centre, and the racemate of (R)- and (S)-thalidomide was introduced as a sedative drug in the late 1950s. In 1961, it was withdrawn due to teratogenicity and neuropathy. There is now a growing clinical interest in thalidomide due to its unique anti-inflammatory and immunomodulatory effects.To critically review pharmacokinetic ...
T, Eriksson, S, Björkman, P, Höglund
openaire +2 more sources
Clinical Pharmacology and Adolescence
Pediatric Clinics of North America, 1980When determining the type and timing of drug therapy for adolescents, certain biological and psychosocial factors unique to this age group must be considered. Modern drug monitoring techniques allow the physician to more successfully treat the adolescent patient.
openaire +2 more sources
Clinical Pharmacology of Famotidine
Digestion, 2009The results of the initial clinical pharmacology studies of famotidine, a new H<sub>2</sub> receptor antagonist, are summarized. These studies indicate that: (1) single oral doses of famotidine (5–80 mg) were well tolerated; (2) famotidine effectively suppressed basal, nocturnal, pentagastrin- and meal-stimulated acid secretion; (3) the ...
openaire +2 more sources
Clinical Pharmacology of Nicotine
Annual Review of Medicine, 1986Nicotine is the primary reason why people consume tobacco products and it may contribute to causation of tobacco-related diseases. This chapter reviews the human pharmacology of nicotine, the evidence for a role of nicotine in human disease, and the use of nicotine (gum) as a therapeutic agent in smoking cessation therapy.
openaire +2 more sources
Clinical Pharmacology of Valpromide
Clinical Pharmacokinetics, 1991Valpromide has been used as an antiepileptic and antipsychotic drug for the past 25 years in several European countries. Unlike its corresponding acid, valproic acid, whose pharmacokinetics have been quite extensively reviewed, and despite years of clinical use, it appears that no reviews have been written on the pharmacokinetics of valpromide.
openaire +2 more sources
Clinical pharmacology in Canada
Clinical Pharmacology & Therapeutics, 1974Information obtained from a poll of Canadian academic authorities concerning the extent of the need for and role to be served by clinical pharmacology is presented and discussed. Current problems are identified, the implications of the regulatory control of drug testing and marketing are explored, and recommendations for future action are outlined.
openaire +2 more sources
The clinical pharmacology of oxazepam
Acta Psychiatrica Scandinavica, 1978The benzodiazepines have been available now for about 1.5 years but new aspects of their actions are being elucidated all the time. Oxazepani has a short half‐life and inactive metabolites and therefore differs from most other benzodiazepines. Some aspects of its clinical pharmacology are reviewed in outline.
openaire +2 more sources